Dr. Schneiderman on Cancer Drugs and Futility Policies

Lawrence J. Schneiderman, MD
Published: Tuesday, Mar 18, 2014

Lawrence J. Schneiderman, MD, professor emeritus, Medicine/Family & Preventive Medicine, University of California, San Diego (UCSD), discusses futility policies in relation to cancer drugs.

Schneiderman says that physicians can affect sick patients in many ways, but if the patient is too sick to benefit from a treatment, then that treatment should be declared futile.

At UCSD, there is a futility policy in place that states any treatment that does not have a reasonable chance of benefitting a patient should be considered futile and not obligatory. The American Medical Association’s Code of Medical Ethics says all hospitals should have a futility policy, Schneiderman says.

Physicians are sometimes concerned that a patient, or, more likely, a family will demand a treatment. The fact remains, Schneiderman says, that a patient or family can refuse a treatment but cannot demand a treatment.

Lawrence J. Schneiderman, MD, professor emeritus, Medicine/Family & Preventive Medicine, University of California, San Diego (UCSD), discusses futility policies in relation to cancer drugs.

Schneiderman says that physicians can affect sick patients in many ways, but if the patient is too sick to benefit from a treatment, then that treatment should be declared futile.

At UCSD, there is a futility policy in place that states any treatment that does not have a reasonable chance of benefitting a patient should be considered futile and not obligatory. The American Medical Association’s Code of Medical Ethics says all hospitals should have a futility policy, Schneiderman says.

Physicians are sometimes concerned that a patient, or, more likely, a family will demand a treatment. The fact remains, Schneiderman says, that a patient or family can refuse a treatment but cannot demand a treatment.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x